✦ LIBER ✦

Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?

✍ Scribed by Scartozzi, Mario; Mazzanti, Paola; Giampieri, Riccardo; Berardi, Rossana; Galizia, Eva; Gasparini, Stefano; Zuccatosta, Lina; Cascinu, Stefano

Book ID: 119320238
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 213 KB
Volume: 68
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2009.07.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictive Factors for Mediastinal Nodal

Predictive Factors for Mediastinal Nodal Failure in Locally-advanced Non–small–cell Lung Cancer (NSCLC) Patients Receiving Definitive Radiotherapy (RT)

✍ A. Fernandes; L. Lin; J. Shen; J. Finlay; T. Evans; C. Langer; J. Stevenson; E. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Third-line therapy for advanced non-smal

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients

✍ Zhengbo Song; Yongfeng Yu; Zhiwei Chen; Shun Lu 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 387 KB

Factors associated with the likelihood o

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer

✍ Hensing, Thomas A.; Schell, Michael J.; Lee, Ji-Hyun; Socinski, Mark A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Weekly docetaxel as first-line therapy f

Weekly docetaxel as first-line therapy for elderly patients with advanced non-small cell lung cancer (NSCLC)

✍ Hainsworth, J.D; Burris, H.A; Morrissey, L.H; Litchy, S; Greco, F.A 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Clinical surrogate markers of survival i

Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second–third line erlotinib

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

CYFRA 21-1 level predicts survival in no

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

✍ Barlési, F; Tchouhadjian, C; Doddoli, C; Torre, J-P; Astoul, P; Kleisbauer, J-P 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 64 KB